DNAtrix is advancing virus-driven immunotherapies in multiple clinical trials for the treatment of cancer.
DNAtrix's platform technology leverages the unique characteristics of viruses to create a pipeline of potent therapies for hard-to-treat cancers that have shown resistance to conventional therapies.
Our pipeline of clinical stage cancer therapies includes DNX-2401 (tasadenoturev) and DNX-2440. These therapies have demonstrated the ability to selectively kill tumor cells and stimulate long term antitumor immune responses.
These therapies have demonstrated the ability to selectively kill tumor cells and stimulate long term antitumor immune responses.
DNAtrix’s lead program, DNX-2401, is an oncolytic immunotherapy engineered specifically to infect, replicate in, and directly kill cancer cells, as well as elicit a broad anti-tumor immune response. DNX-2401 is currently being evaluated as a potential treatment for highly aggressive brain tumors, including glioblastoma in adults and diffuse intrinsic pontine glioma (DIPG) in children. Clinical studies have demonstrated that DNX-2401 is well tolerated and may lead to extended survival for patients with recurrent glioblastoma (rGBM). For rGBM, DNX-2401 has been granted: Fast Track and Orphan designation by the FDA; Priority Medicines (PRIME) and Orphan designations by the EMA; and Promising Innovative Medicine Designation (PIM) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). For DIPG, DNX-2401 has been granted Fast Track & Rare Pediatric Disease designations by the FDA.
DNX-2440 is a next-generation, oncolytic immunotherapy encoding human OX40 ligand (OX40L, CD252, TNFSF4) developed to treat cancer, including metastatic disease. In addition to direct tumor cell killing and immune stimulation, the expression of OX40L enhances the anti-tumor immune response by providing co-stimulatory signals to T-cells. DNX-2440 is in Phase 1 clinical testing following the demonstration of robust anti-cancer activity in preclinical studies, including tumor reduction, immune memory, and abscopal anti-tumor activity in distant tumors.
DNAtrix is continuing to expand its pipeline of cancer immunotherapies by developing oncolytic viruses armed with potent immunomodulatory molecules designed to unleash immune responses against tumors.
DNAtrix's office is located in San Diego, California.